90 micron flaps get the thumbs up

Article

Using a femotsecond laser (IntraLase) to create flaps of 90 microns does not increase the postoperative risk of striae formation or induction of optical aberrations.

Using a femotsecond laser (IntraLase) to create flaps of 90 microns does not increase the postoperative risk of striae formation or induction of optical aberrations, according to Omid Kermani and colleagues from Augenklinik am Neumarkt, Cologne, Germany.

A total of 25 eyes (18 patients) were treated with the femtosecond laser, applying an intended thickness of 90 microns. A further 25 eyes (14 patients) received LASIK flap cuts with a conventional microkeratome (MK 2000; Nidek), applying an intended flap thickness of 130 microns. All eyes were treated for myopia or myopic astigmatism with the Nidek EC CXIII refractive excimer laser.

No vision threatening complications occurred in any of the treatments and in all eyes, the flap could be opened and repositioned after laser ablation. Dr Kermani conceded that the 90 micron flaps were slightly more difficult to lift compared with normal femtosecond flaps of 120 microns.

The mean femtosecond flap thickness was 95 microns with a standard deviation of ±10 microns and the mean microkeratome flap thickness was 115 microns with a standard deviation of ±25 microns.

Ninety percent of all eyes (from both groups) were within ±0.5 D of target refraction and one day after LASIK, all eyes had a visual acuity of 0.8 or more. Furthermore, no eyes lost more than one line of best corrected visual acuity.

Dr Kermani concluded that flaps with a thickness below 100 microns were not associated with an increased postoperative risk.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.